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Abstract
Aspirin has been shown to protect against colorectal neoplasms, however the optimal 
chemopreventive dose and underlying mechanisms are unclear. We aimed to study the relationship 
between prostanoid metabolites and aspirin’s effect on adenoma occurrence. We used data from 
the Aspirin/Folate Polyp Prevention Study, in which 1,121 participants with a recent adenoma 
were randomized to placebo or two doses of aspirin (81 or 325 mg/d) to be taken until the next 
surveillance colonoscopy, anticipated about 3 years later. Urinary metabolites of prostanoids 
(PGE-M, PGI-M, and dTxB2) were measured using LC/MS or GC/NICI-MS in 876 participants 
near the end of treatment follow-up. Poisson regression with a robust error variance was used to 
calculate relative risks and 95% confidence intervals. PGE-M, PGI-M, and dTxB2 levels were 
28%, 37%, and 60% proportionately lower, respectively, in individuals who took 325 mg of 
aspirin compared to individuals who took placebo (all P<0.001). Similarly, among individuals 
Corresponding author: Veronika Fedirko, PhD, Department of Epidemiology, Rollins School of Public Health, Winship Cancer 
Institute, Emory University, Atlanta, GA, vfedirk@emory.edu. 
Conflict of interest
Dr. Baron and Dartmouth College hold a use patent for the chemopreventive use of aspirin, currently not licensed.
HHS Public Access
Author manuscript
Cancer Prev Res (Phila). Author manuscript; available in PMC 2016 November 01.
Published in final edited form as:













who took 81 mg of aspirin, PGE-M, PGI-M, and dTxB2 were, respectively, 18%, 30%, and 57% 
proportionally lower compared to placebo (all P<0.005). None of the metabolites or their ratios 
were statistically significantly associated with the risk of adenoma occurrence. The effect of 
aspirin in reducing adenoma risk was independent of prostanoid levels. Aspirin use is associated 
with lower levels of urinary prostanoid metabolites. However, our findings do not support the 
hypothesis that these metabolites are associated with adenoma occurrence, suggesting that COX-
dependent mechanisms may not completely explain the chemopreventive effect of aspirin on 
colorectal neoplasms.
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INTRODUCTION
There is strong evidence from observational studies and randomized clinical trials that 
aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are protective against 
colorectal neoplasms (1–5), however the dose-response relationship and underlying 
antineoplastic mechanisms are not clear. Pooled results from four clinical trials with 2,967 
participants randomly assigned to doses of aspirin from 81 to 325 mg daily showed a 
borderline statistically significant 15% decrease in any adenoma occurrence, and a 
statistically significant 29% decrease in advanced adenoma occurrence with higher-dose 
aspirin supplementation (≥300 mg/d)(6). Interestingly, in a combined analysis of the two 
trials (2, 5) [including ours (2)] that tested higher (300 or 325 mg/d) and lower (≤160 mg/d) 
doses of aspirin versus placebo, lower-dose aspirin showed statistically significantly greater 
risk reduction for all colorectal adenomas than higher-dose aspirin (6).
Prostanoids, important mediators of human physiology, are a subclass of eicosanoids 
consisting of the prostaglandins (PGs), the prostacyclins, and the thromboxanes. They are 
generated from the precursor arachidonic acid by cyclooxygenase (COX) enzymes: COX-1, 
constitutively expressed in the luminal gastrointestinal tract and responsible for the 
production of cytoprotective PGs; and COX-2, inducible by a variety of factors such as 
growth factors and mitogens, and a central element of the inflammatory response (7). The 
increased activity of COX-2 plays an important role in colorectal carcinogenesis (8, 9); the 
involvement of COX-1 has been less investigated, but also appears to be involved (10). Of 
the PGs, prostaglandin E2 (PGE2) is likely to be the primary mediator of COX pro-
carcinogenic effects (8).
Thromboxane A2 (TXA2) and prostacyclin (PGI2) are other prostanoids, both well known to 
regulate cardiovascular homeostasis: TXA2 stimulates vasoconstriction and platelet 
aggregation, whereas prostacyclin PGI2 promotes vasodilatation and inhibits platelet 
aggregation (8). In addition to their cardiovascular effects, both PGI2 and TXA2 appear to 
affect carcinogenesis. Thromboxane A2 activation of platelets leads to the release of 
mediators of carcinogenesis, and TXA2 itself seems to act as a pro-carcinogenic factor (10–
13). On the other hand, PGI2 seems anticarcinogenic (14): lower levels are seen in 
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neoplastic tissue (15–17), in vitro and in vivo studies suggest interference with 
carcinogenesis (12, 18), and studies of the prostacyclin synthase gene point to anti-
neoplastic effects as well (19, 20).
Low doses of aspirin are sufficient to reduce PGE2 levels in the colorectal mucosa, with no 
additional increase in inhibition with doses above 81 mg per day (21–25). There have been 
no studies of the effects of aspirin on PGI2 or TXA2 in the large bowel mucosa, but higher 
doses are generally required to substantially modulate systemic prostacyclin production (26–
29), while lower doses are effective in inhibiting platelet TXA2, and increasing the ratio of 
PGI2 to TXA2 (30–32). If prostacyclin has anti-neoplastic properties, aspirin doses above 81 
mg would then lose preventive potency from the inhibition of this potentially anti-neoplastic 
prostanoid.
To understand the role of PGE2, PGI2, and TXA2, in colorectal carcinogenesis, we 
conducted secondary analyses in the Aspirin/Folate Polyp Prevention Study (AFPPS) (2, 
33), a clinical trial of aspirin and/or folic acid for the prevention of occurrence of colorectal 
adenomas. Our aims were to assess the effect of two doses of daily aspirin intake on urinary 
prostanoid metabolites; to investigate whether urinary prostanoid metabolites are associated 
with risk for recurrent adenoma diagnosed during treatment; and to examine whether a 




These data were collected as part of the AFPPS, a randomized, double-blind, placebo-
controlled, three-by-two factorial trial testing whether oral aspirin (81 or 325 mg daily) or 
folic acid (1 mg daily) reduces the risk of new colorectal adenomas (clinicaltrials.gov 
identifier: NCT00272324) (2, 33).
Recruitment, randomization, treatment, and follow-up
Details of subject eligibility, recruitment, randomization, treatment, and follow-up, and 
study outcomes have been previously described (2, 33). Briefly, patients with a recent 
history of colorectal adenomas were recruited between during 1994–1998 from nine clinical 
centers in the US and Canada. Eligible subjects were between 21 and 80 years of age, in 
good health, had a complete colonoscopy within 3 months before enrollment with no known 
polyps left in the bowel, and had received a recommendation for a 3-year follow-up 
colonoscopy by their regular medical practitioner.
At enrollment, eligible subjects completed a questionnaire regarding demographics, medical 
history, and lifestyle habits. All participants were asked to avoid the use of aspirin, NSAIDs, 
and supplements containing folate for the duration of active treatment. Each subject 
underwent a three-month, single-blind run-in period on 325 mg of aspirin per day. Only 
subjects with at least 80% compliance and no adverse effects of aspirin were randomly 
assigned to receive aspirin placebo, low-dose aspirin (81 mg/d), or high-dose aspirin (325 
mg/d), and to receive folate placebo or folate (1 mg/d). A total of 1,021 full factorial 
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subjects were randomized, as well as 100 “aspirin-only” subjects who were recruited before 
the folic acid component of the study was added.
By protocol, participants were to remain on study treatment until their anticipated 
surveillance colonoscopy, about three years after the qualifying exam. Every 4 months 
during study treatment subjects completed a questionnaire regarding compliance with study 
agents, use of medications and supplements, large bowel endoscopy, and medical events. In 
addition to a baseline blood sample, blood and spot urine samples were obtained late in the 
third year of participation, and stored at −70°C. Compliance in the initial 3-year treatment 
period was excellent: 87% to 95% of subjects took study pills at least 6 days per week 
during those three years. All study aspirin treatment ended on September 28, 2001.
Study outcomes
The primary outcome — adenoma occurrence — was determined by colonoscopy and 
confirmed by pathology review. All lesions removed from the large bowels of study subjects 
were reviewed by a single study pathologist. Polyps were classified as adenomatous, 
hyperplastic, serrated or other polyps; the degree of dysplasia and the extent of villous 
component in each adenoma were recorded. Low-risk adenomas were defined as solitary 
adenomatous polyps < 1 cm in greatest diameter with tubular histology. Advanced 
adenomas were defined as adenomatous polyps with an estimated diameter of ≥1 cm, or at 
least 25% villous component, any high-grade dysplasia, or invasive cancer. “High risk 
findings” were one or more advanced adenomas or two or more low risk adenomas [for 
comparability with previous studies (34, 35)].
Laboratory Measurements
Catabolism of PGE2 results in an end metabolite, 11-α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-
prostane-1,20-dioic acid (PGE-M), that is excreted in the urine and stable for prolonged 
periods when stored at −70°C (36). Measurement of urine PGE-M is a better measure of 
systemic PGE2 production than plasma measurements (37, 38) because PGE2 in plasma is 
rapidly metabolized in the lungs and consequently may not accurately reflect endogenous 
prostaglandin production (39). We measured urinary PGE-M using liquid chromatography-
mass spectrometry (LC/MS) as previously described (40) on a Waters Acquity UPLC 
coupled to a Thermo Scientific Quantum Vantage triple quadruple mass spectrometer.
2,3-dinor-6-keto-PGF1α (PGI-M), a major urinary metabolite of prostacyclin PGI2, was 
measured using gas chromatography-negative-ion chemical ionization mass spectrometry 
(GC/NICI-MS) as previously described (41) on an Agilent 5973 Inert Mass Selective 
Detector coupled with an Agilent 6890n Network GC system (Agilent Labs, Torrance, CA). 
11-dehydro-thromboxane B2 (dTxB2), a major urinary enzymatic metabolite of 
thromboxane A2, was measured using GC/NICI-MS as previously described (42) using the 
same instruments as described above for PGI-M.
PGE-M, PGI-M, and dTxB2 were successfully measured in 871, 816, and 854 samples, 
respectively, in the Eicosanoid Core Laboratory at Vanderbilt University. The lower limit of 
detection of PGE-M and PGI-M was 15 pg/mg creatinine, and of dTxB2, 20 pg/mg 
creatinine. Inter-day and intra-day variability was less than 10% for all prostanoids assays. 
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Quality control samples, from a pooled urine collection, were included with each batch 
analyzed. Between-batch coefficients of variation were 8.38%, 5.92%, and 7.32%, for the 
PGE-M, PGI-M, and dTxB2 assays, respectively. Urinary prostanoid metabolite levels were 
expressed as pg/mg of analyte per mg of urinary creatinine. Urinary creatinine was 
measured using a chemical assay based on Jaffe’s reaction according to the manufacturer’s 
instructions (Enzo Life Sciences, NY, USA). Laboratory staff was blinded to the treatment 
group assignment of urine samples and the identity of quality control samples included in 
the study. Samples from each treatment group were randomly included in every batch.
Statistical Analyses
Levels of urinary biomarkers were natural log transformed to improve normality. Values 
below limit of detection (LOD) were replaced by LOD/2 [n = 4 (0.5%) for PGE-M, n = 61 
(7.5%) for PGI-M, and n = 4 (0.5%) for dTxB2]. Fisher exact tests (for categorical variables) 
and analysis of variance (for continuous variables) were used to compare randomized 
treatment groups. Correlations between biomarkers were calculated using Spearman’s 
correlation coefficient (ρ). We used modified Poisson regression with a robust variance 
estimate to calculate the relative risks (RR) and 95% confidence intervals (CIs) of having at 
least one adenoma (43). Covariates in multivariable models included age (continuous), sex, 
clinical center, number of lifetime adenoma before randomization (continuous), follow-up 
time (continuous), and aspirin treatment group assignment (placebo, 81 mg/d, or 325 mg/d). 
In secondary analyses, we further adjusted for randomized folic acid treatment, first degree 
family history of colorectal cancer (yes/no), body mass index (<25, 25 – 30, ≥ 30 kg/m2) at 
study enrollment, alcohol use (yes/no), smoking status (never/former/current). Inclusion of 
these covariates in the models did not substantially change the results; therefore, only the 
most parsimonious models are presented. Adjusted estimates are presented for one or more 
adenomas, low-risk adenomas, or advanced adenomas, and high-risk findings. The ratio of 
PGE-M to PGI-M was used as an indicator of trade-off between systemic PGE2 and PGI2 
production. Since PGE2 and thromboxane A2 are hypothesized to be pro-carcinogenic, and 
PGI2 possibly anti-carcinogenic, we used the ratio of (PGE-M + dTxB2) to PGI-M as an 
indicator of the overall balance between potentially pro- and anti-carcinogenic effects of 
prostanoids. The P-value for trend was calculated using the continuous biomarker levels 
entered linearly into the models. An interaction by aspirin treatment assignment (placebo, 81 
mg/d, or 325 mg/d) was assessed by including the cross product of the treatment variable 
and urinary biomarker, and evaluated using the Wald test. To compare our results with 
previous findings (35), we conducted an analysis of aspirin treatment effects within low 
(first tertile) and high (second and third tertiles) PGE-M levels. All statistical tests were two-
sided. Statistical analysis was conducted using Stata (version 12.1, Stata Corp, College 
Station, TX).
RESULTS
There were 1,121 individuals randomized to aspirin or placebo, and 1,084 (97%) underwent 
a follow-up examination. A total of 876 participants (80.8% of with a follow-up exam) had 
at least one urinary prostanoid metabolite measurement; 328 had one or more recurrent 
adenoma at the end of treatment follow-up. The baseline characteristics of the subjects in the 
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three aspirin treatment arms with at least one biomarker measurement are shown in Table 1. 
Participants with missing urine measurements (n = 208) were comparable with those 
included in the analysis (n = 876) with respect to baseline characteristics and treatment 
randomization (data not shown). There were no statistically significant differences among 
the three arms with regard to demographic and lifestyle factors at the study entry. The three 
treatment arms were also similar with regard to the percentage of subjects who were 
randomly assigned to folic acid treatment.
Among all study participants, urinary PGE-M levels were weakly correlated with urinary 
PGI-M (ρ = 0.16, P <0.001) and dTxB2 (ρ = 0.30, P <0.001), with a somewhat stronger 
correlation between urinary PGI-M and dTxB2 (ρ = 0.41, P <0.001). Similar correlations 
were found in each treatment group (data not shown). Urinary PGE-M, PGI-M and dTxB2 
differed by sex, age, study center, and smoking status (Supplementary Tables 1 and 2). 
Aspirin treatment was associated with lower urinary prostanoid metabolites levels in a dose-
dependent manner (Figure 1). Urinary PGE-M levels were proportionately 28% and 18% 
lower in participants who took 325 mg and 81 mg of aspirin, respectively, compared to 
participants who took placebo. Similar but weaker dose-dependent patterns were observed 
for PGI-M and dTxB2. However, the ratios of PGE-M to PGI-M, and of (dTxB2 + PGE-M) 
to PGI-M did not differ substantially by aspirin treatment group (Supplementary Table 3). 
Comparable aspirin-associated decreases in the levels of urinary prostanoid metabolites 
were observed in the data further stratified by the folic acid treatment arm (Supplementary 
Table 4).
There was no evidence that urinary PGE-M, PGI-M, or dTxB2 concentrations (or their 
ratios) were associated with risk for any adenoma: RR’s quartiles 2 through 4 were each 
close to 1.0, with narrow confidence intervals. Urinary PGE-M, PGI-M, and dTXB2 also 
had no material associations with low risk adenomas or high risk findings (Table 2). In 
contrast, the PGE-M, PGI-M, and to a lesser extent dTXB2, showed non-significant 
suggestions of decreasing RR trends with increasing urinary levels for advanced adenomas 
(Table 2). The ratios of PGE-M to PGI-M, and of (dTxB2 + PGE-M) to PGI-M were 
unassociated with risk of any adenomas class (Supplementary Table 5). None of the 
interactions of urinary prostanoid levels with aspirin treatment group were statistically 
significant (all P > 0.1). We repeated the analyses in the placebo group only and obtained 
similar findings (Supplementary Table 6).
In an exploratory analysis, in which we stratified the study participants according to PGE-M 
levels (Figure 2), aspirin treatment was associated with a significant reduction in any and 
high-risk adenoma occurrence among participants with low PGE-M (<5.34 ng/mg 
creatinine), but not among participants with high PGE-M (≥5.34 ng/mg creatinine) 
concentrations; however neither of the interactions were statistically significant. A similar 
pattern was suggested for low-risk adenoma, whereas for advanced adenoma the aspirin 
treatment effects did not seem to differ by PGE-M levels. Analyses stratified by sex 
(Supplementary Tables 7 and 8) suggested that among women, higher levels of PGE-M may 
be positively associated with adenoma occurrence; however, the results were based on a 
very small number of events and no statistically significant multiplicative interactions by sex 
were found.
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Two participants in the low-dose aspirin group and three in the high-dose aspirin group were 
classified as aspirin resistant based on dTxB2 > 1.5 ng/mg creatinine (>67.9 ng/mmol of 
creatinine)(44, 45). Among the 5 participants, one did not take the study treatment (0% 
compliance). The exclusion of these subjects from the analysis had no effect on the risk 
estimates (data not shown).
DISCUSSION
In this analysis of individuals participating in a randomized clinical trial, aspirin treatment 
was associated with lower levels of urinary prostanoids in a dose-dependent manner: 
participants who took high-dose aspirin had the lowest concentrations of PGE-M, PGI-M, 
and dTxB2 compared to participants who took low-dose of aspirin or placebo. None of the 
urinary prostanoid metabolites or their ratios were significantly associated with risk of any 
measure of adenoma risk.
The levels of COX-derived PGE2 and its synthase are increased in colorectal neoplasia as 
compared with histologically normal tissue.(16, 46, 47) PGE2 has been shown to inhibit 
apoptosis, promote cellular proliferation, angiogenesis, and migration, and activate Wnt 
signaling (48, 49). In previous studies, the major urinary metabolite of PGE2, PGE-M, has 
been strongly directly associated with the risk of colorectal cancer (50) and (contrary to our 
findings) with multiple and/or advanced adenoma (RR ranging from 1.66 to 2.19 comparing 
the highest vs. lowest quartiles) (34, 35). Conversely, in our study, the association pattern for 
PGE-M with advanced adenomas was non-significantly suggestive of an inverse association. 
In agreement with our results, previous studies have not found an association with single 
small tubular adenoma (34, 35) or any adenoma (35). There are no previous data regarding 
the associations of metabolites of PGI2 and thromboxane with risk of colorectal cancer or 
adenomas of any type.
Our data suggested that aspirin treatment was associated with a significant reduction in 
adenoma occurrence in participants with low PGE-M, measured near the end of treatment. 
This is expected, since both adenoma occurrence and low PGE-M levels are associated with 
aspirin use and so are logically associated with each other. Trial participants on aspirin 
tended to have low PGE-M and also had the lowest adenoma risk. On the other hand, 
participants with high PGE-M tended to be placebo subjects (or aspirin subjects resistant to 
treatment) and had a higher risk for adenomas. Bezawada et al (35) also investigated this 
issue, and reported the opposite pattern: stronger aspirin/NSAIDs associations in women 
with higher urinary PGE-M. To the extent that their samples were truly baseline (taken 
before starting aspirin), their data are logical and do not conflict with ours. However, to the 
extent their data were taken “on treatment” (during aspirin/NSAID use) the two studies 
disagree. It is not clear whether their samples were truly baseline as they were collected at 
the same time as information on aspirin/NSAID use.
Thromboxane is essential to platelet activation, and the antiplatelet effect of aspirin through 
inhibition of thromboxane synthesis seems to be relevant to its anti-neoplastic actions (11). 
It has been proposed that activated platelets promote COX-2 upregulation in adjacent cells 
of the colorectal mucosa at sites of mucosal injury via paracrine lipid (e.g., TXA2) or protein 
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(e.g., interleukin-1β) mediators (11). There may also be direct effects of TXA2 itself, as 
mucosal levels stimulate proliferation, promote metastases, and mediate COX-2-dependent 
angiogenesis (13, 51–53). Elevated levels of TXA2 and thromboxane synthase in colorectal 
neoplasms have been reported, (13, 17) and colon cancer cells that overexpress the TXA2 
synthase gene grow faster and exhibit more abundant vasculature (12). In our study, higher 
levels of dTxB2, a major urinary metabolite of TXA2, were not associated with the risk of 
any adenoma. In contrast to our initial hypothesis, the association pattern for dTxB2 was 
suggestive of an inverse association for advanced adenoma at the end of study follow-up 
among all and placebo-only participants.
Prostacyclin PGI2, a prostaglandin downstream of COX-1 and COX-2 (54), has important 
roles in cardiovascular homeostasis, and may also influence carcinogenesis. Expression of 
PGI2 seems reduced in lung cancers (15), and administration of a PGI2 analogue improves 
endobronchial dysplasia in former smokers (18). Colon cancer cells that overexpress the 
prostacyclin synthase gene (PTGIS) grow more slowly and with less developed vasculature 
than control inoculants (12). Epigenetic inactivation of the PTGIS is common in colorectal 
cancer (19), and reduced tumor tissue levels of PGI2 compared with adjacent normal mucosa 
have been reported (16, 17). Furthermore, a polymorphism associated with reduced activity 
of the PTGIS gene has been associated with an increased risk of colorectal adenomas and a 
blunting of the protective effect of NSAIDs (20). Our results show that PGI-M, a major 
urinary metabolite of PGI2, was not associated with any adenoma, but – in agreement with 
our initial hypothesis – higher levels of PGI-M were non-significantly inversely associated 
with advanced adenoma.
Although numerous epidemiological studies and several randomized clinical trials reported 
that aspirin is protective against colorectal neoplasms (1–5); it is unknown exactly how it 
exerts its anti-neoplastic effects, and why the lower aspirin dose seems more effective in 
preventing colorectal adenomas. The main proposed mechanism so far includes inhibition of 
COX enzymes. We also hypothesized that a trade-off between pro-carcinogenic PGE2 
and/or TXA2, and putatively anti-carcinogenic PGI2 may explain a protective effect of lower 
dose aspirin. However, our findings did not suggest that differential inhibition of prostanoids 
explains the paradoxical aspirin effects, nor support the COX-dependent anti-neoplastic 
effects of aspirin, as urinary prostanoid metabolites were not associated with risk for 
colorectal adenoma occurrence. It is possible that COX-independent effects of aspirin are 
involved, including inhibition of PPARδ (55) and oxidative DNA damage (56), modulation 
of polyamine metabolism (57) and Wnt signaling (58), activation of the NF-kB signaling 
pathway resulting in apoptosis (59), increase in leukotriene production as a result of 
shuttling of free arachidonic acid between COXs and lipoxygenases pathways (58), and 
activation of the NSAID-activated gene (NAG-1) (60), which is a member of the TGF-β 
family that has pro-apoptotic and anti-tumorigenic activities (61).
This study has several limitations. First, participants in this analysis had a previous history 
of at least one colorectal adenoma, potentially limiting the generalizability of the data. In 
particular, it is possible that the colorectal mucosa that has had prior adenoma may already 
have altered prostanoid signaling (e.g., a deficiency in 5-Hydroxyprostaglandin 
dehydrogenase [15-PGDH]), which may efface the differences in levels between those who 
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do, and do not, have a recurrent adenoma on a later colonoscopy. Second, we did not 
measure the prostanoids concentrations at the study entry, as we did not collect urinary 
samples at that time. However, the on-treatment measurements better reflect the subjects’ 
metabolic milieu during the period the adenomas were forming. Third, the ratios of PGE-M 
and dTxB2, individually and in combination, to PGI-M may not adequately capture trade-off 
between systemic productions of these prostanoids. Fourth, treatment effects of aspirin on 
the prostanoid synthesis in the colon mucosa are unclear, as we did not measure the 
expression of prostanoids in the colorectal tissue. Finally, we had a limited sample size to 
investigate risk of advanced adenoma occurrence.
The strengths of this study include the randomized, placebo-controlled trial design; high 
protocol adherence by study participants; the high follow-up rate; and the systemic 
collection of risk factor information at baseline and follow-up intervals as well as outcomes 
at the end of treatment. Another strength of this study is that we measured stable biomarkers 
of systemic production of prostanoids using highly sensitive assays in one laboratory. 
Finally, this study is the first human study to investigate the association between PGI-M and 
dTxB2 and risk of colorectal adenoma.
Overall, in this study, we found that low- and high-dose aspirin is associated with lower 
levels of urinary prostanoid metabolites in a dose-dependent manner. However, our findings 
provided no evidence that urinary prostanoid metabolites are associated with reduced risk of 
colorectal adenoma occurrence. In agreement with our original hypothesis, we observed a 
possible inverse association of metabolites of the possibly anti-carcinogenic prostanoid PGI2 
with advanced adenoma occurrence. However similar inverse associations were observed for 
other potentially pro-carcinogenic prostanoids. Studies of colorectal neoplasms that measure 
changes in both systemic and tissue-specific levels of prostanoids in response to aspirin 
treatment are needed to confirm our results.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Urinary PGE-M (A), PGI-M (B) and dTxB2 (C) levels by aspirin treatment group, the 
Aspirin/Folate Polyp Prevention Study.
* P-value vs. placebo. ** The proportional difference in geometric means was calculated as 
([treatment group – placebo group]/placebo group)*100%. *** P-value vs. 81 mg.
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Association of adenoma occurrence during study treatment within categories of urinary 
PGE-M levels by aspirin treatment group, the Aspirin/Folate Polyp Prevention Study. All 
models were adjusted for age (continuous), sex, center (categorical), number of previous 
adenomas (continuous), and follow-up time (continuous). Placebo was the reference group. 
Low PGE-M category = tertile 1, High PGE-M category = tertile 2 & tertile 3.
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(N = 284) P-value
Age, yrs, mean (SD) 57.5 (9.8) 57.2 (9.4) 57.6 (4.5) 0.88
Male sex, no. (%) 189 (63.9) 193 (65.2) 178 (62.7) 0.83
White, no. (%) 253 (85.5) 260 (87.8) 250 (88.0) 0.14
BMI, kg/m2*, mean (SD) 27.3 (4.5) 27.3 (4.5) 27.7 (4.8) 0.91
Overweight, no. (%) 140 (47.5) 142 (48.1) 130 (45.8)
0.89
Obese, no. (%) 63 (21.4) 60 (20.3) 70 (24.7)
Current smoker, no. (%) 41 (13.9) 40 (13.6) 41 (14.5) 0.56
Alcohol drinker, no. (%) 199 (67.3) 189 (63.9) 193 (68.0) 0.62
Multivitamin use, no. (%) 104 (35.1) 111 (37.5) 96 (33.8) 0.40
Family history of colorectal polyps, no. (%) 62 (26.8) 72 (29.2) 77 (34.1) 0.13
Adenoma characteristics (at baseline)**
Number, mean (SD) 1.6 (0.9) 1.6 (1.0) 1.6 (1.1) 0.41
Advanced adenomas, no. (%)*** 84 (36.1) 80 (34.9) 89 (39.6) 0.69
Proximal location, no. (%) 136 (54.4) 135 (54.0) 133 (55.0) 0.74
Folic acid treatment group, no. (%) 149 (51.0) 147 (49.7) 143 (50.7) 0.98
*
N=1 in the placebo, and N=1 in the aspirin 81 mg/d group had missing BMI data.
**
Data available for 268, 257, 243 participants in the placebo, aspirin 81 mg/d, and aspirin 325 mg/d treatment groups, respectively.
***
Data available for 233, 229, and 229 in the placebo, aspirin 81 mg/d, and aspirin 325 mg/d treatment groups, respectively.
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